Orchestra BioMed Holdings, Inc. OBIO

5.95 0.00 0.00% as of 25 Sep
Market cap
$366.0M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(607.32%) (189.00%) (122.40%) (166.97%)

+8 more TTM periods

ROA
(75.16%) (68.69%) (55.44%) (83.39%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(59.68%) (65.02%) (57.01%) (95.42%)
Average Days of Receivables
0.58 0.94 1.04 6.74
Free Cash Flow per Share
(0.93) (0.88) (1.04) (1.16)
Free Cash Flow
(59.10) (55.08) (49.45) (60.79)
Capital Expenditures
(0.78) (0.56) (0.49) (0.56)
Piotroski F-Score
6.00 6.00 6.00 4.00
Other line items
Cash ROIC
(35.53%) (36.36%) (28.08%) (39.17%)
Accounts Receivable Turnover
477.25 378.31 358.10 33.75
Accounts Payable Turnover
0.03 0.03 0.03 0.03
Inventory Turnover
0.72 0.86 0.79 0.66
Average Days of Payables
14,255.92 12,945.20 11,708.82 15,698.71
Days of Inventory on Hand
581.21 568.01 595.53 676.27
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
197.71% 184.83% 173.78% 1,857.10%
Selling, General and Administrative Expense of Revenue
83.15% 82.58% 80.38% 905.82%
Share Based Compensation of Revenue
34.77% 36.25% 35.77% 430.45%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
0.98 0.99 0.92 0.80
Depreciation/Fixed assets
0.29 0.31 0.32 0.32
Capex/Depreciation
(1.30) (0.99) (0.90) (1.10)
Revenue per Share
0.50 0.52 0.70 0.05
Operating CF per Share
(0.91) (0.87) (1.03) (1.15)
Capex per Share
(0.01) (0.01) (0.01) (0.01)
Capex to Sales
0.02 0.02 0.01 0.20
Net Profit Margin
(186.30%) (167.63%) (158.16%) (2,665.05%)

Fold the line items

Columns are period end dates